| anti-SARS-CoV-2 virus inactivated plasma / Wuhan University |
ChiCTR2000030929: A randomized, double-blind, parallel-controlled trial to evaluate the efficacy and safety of anti-SARS-CoV-2 virus inactivated plasma in the treatment of severe novel coronavirus pneumonia (COVID-19) |
|
|
| Not yet recruiting | N/A | 60 | China | Anti-SARS-CoV-2 virus inactivated plasma ;Ordinary plasma | Renmin Hospital of Wuhan University; Renmin Hospital of Wuhan University, Sinopharm Wuhan Blood Products Co., Ltd. | Novel Coronavirus Pneumonia (COVID-19) | | | | |
| allogeneic human dental pulp stem cells / Utooth Biological Technology, Wuhan University, Beijing SH Bio-Tech Corporation |
NCT04336254: Safety and Efficacy Study of Allogeneic Human Dental Pulp Mesenchymal Stem Cells to Treat Severe COVID-19 Patients |
|
|
| Recruiting | 1/2 | 20 | RoW | allogeneic human dental pulp stem cells (BSH BTC & Utooth BTC), Intravenous saline injection (Placebo) | Renmin Hospital of Wuhan University, Beijing SH Bio-Tech Corporation, Beijing (CN), Utooth Biological Technology Co., Ltd. Hubei (CN) | COVID-19 | 11/21 | 12/21 | | |
| AZD6482 / AstraZeneca, Wuhan University |
| Suspended | 2 | 80 | RoW | TBO-309 | The George Institute, Heart Research Institute | Acute Ischemic Stroke | 02/26 | 05/26 | | |
| ex vivo expanded gamma delta T-lymphocyte therapy / Wuhan University, Jinan University, GD Kongming Biotech |
NCT04008381: Ex-vivo Expanded γδ T Lymphocytes in Patients With Refractory/Relapsed Acute Myeloid Leukaemia |
|
|
| Recruiting | 1 | 38 | RoW | Ex-vivo Expanded γδ T Lymphocytes | Wuhan Union Hospital, China, Jinan University, China | Acute Myeloid Leukemia | 07/22 | 01/23 | | |
